L. Navale

发表

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma

R. Levy, J. Friedberg, I. Flinn, 2017, The New England journal of medicine.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

J. Cerhan, C. Gisselbrecht, E. W. Van Den Neste, 2017, Blood.

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, C. Jacobson, N. Bartlett, 2017, Blood.

Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr).

J. Berlin, J. Hecht, H. Burris, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)

J. Berlin, A. Venook, J. Hecht, 2005 .

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

A. Ravaud, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

B. Karlan, E. Rasmussen, I. Vergote, 2012, Cancer Chemotherapy and Pharmacology.

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2021, Blood advances.

Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma".

J. Jansen, F. Locke, O. Oluwole, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".

J. Jansen, F. Locke, O. Oluwole, 2020 .

Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

J. Berlin, J. Hecht, R. Amado, 2007 .

B. Monk, R. Coleman, T. Herzog, 2014 .

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

B. Monk, B. Karlan, A. Oza, 2014 .

Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients (PTPs)

G. Spotts, V. Blanchette, L. Navale, 2003 .

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

I. Flinn, D. Miklos, C. Jacobson, 2019, The Lancet. Oncology.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

B. Monk, B. Karlan, A. Oza, 2014, The Lancet. Oncology.

287. Production of KTE-C19 (Anti-CD19 CAR T Cells) for ZUMA-1: A Phase 1/2 Multi-Center Study Evaluating Safety and Efficacy in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

J. Rossi, A. Bot, L. Navale, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies

R. Figlin, A. Belldegrun, A. Tolcher, 2008, Clinical Cancer Research.

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

J. Friedberg, I. Flinn, D. Miklos, 2016 .

Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma.

J. Jansen, F. Locke, O. Oluwole, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

D. Miklos, C. Gisselbrecht, C. Jacobson, 2019, Blood.

Trial of Roflumilast Cream for Chronic Plaque Psoriasis.

M. Lebwohl, Z. Draelos, M. Gooderham, 2020, The New England journal of medicine.

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

D. Miklos, E. Jacobsen, N. Bartlett, 2017 .

Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).

D. Miklos, J. Rossi, C. Jacobson, 2017 .

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

J. Berlin, J. Hecht, A. Venook, 2007, Cancer.

Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr).

J. Hecht, R. Amado, E. Mitchell, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.